Latest
marketscreener.com Earnings
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1–36
- Matches
- 51
- Sources here
- 13
- Companies here
- 4
Search results
Stored financial headlines
Active search
51 matching headlines
Ticker or company: FILAMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Weekly Recap: FDA clinical hold on TSC trial and Q2 2026 cash $82.7M
Filana Therapeutics, Inc. (NASDAQ: FLNA) is facing an active FDA clinical hold on its TSC-related epilepsy trial, hindering progress despite refocusing efforts. The company's Q2 2026 financial results show $82.7M in cash, down from $95.5M, an $8.6M net loss, no debt, and modest R&D …
FLNA
main company
Sharemaestro market context
Stored weekly price path
14 weeks -54.1% · Next-week setup negative 17.6%
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
Filana Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026, including cash and cash equivalents of $82.7 million and a net loss of $8.6 million. The company is actively engaging with the FDA to lift a clinical hold on …
FLNA
main company
Sharemaestro market context
Stored weekly price path
14 weeks -54.1% · Next-week setup negative 17.6%
Maxim Group Maintains Filana Therapeutics(FLNA.US) With Buy Rating, Maintains Target Price $5
Maxim Group has reiterated its Buy rating on Filana Therapeutics (FLNA.US) and maintained its target price of $5. This indicates a continued positive outlook from the analyst group on the company's stock performance.
FLNA
main company
Sharemaestro market context
Stored weekly price path
14 weeks -54.1% · Next-week setup negative 17.6%
Filana Therapeutics Q2 net loss narrows to $8.6 million
Filana Therapeutics (FLNA) reported a narrowed net loss of $8.6 million, or $0.18 per share, for Q2 2026, down from $44.2 million in the prior-year period. The company ended the quarter with $82.7 million in cash and cash equivalents and no debt, while continuing …
FLNA
main company
Sharemaestro market context
Stored weekly price path
14 weeks -54.1% · Next-week setup negative 17.6%
Filana Therapeutics, Inc. Revenue Breakdown – NASDAQ:FLNA
This page provides financial overview information for Filana Therapeutics, Inc. (NASDAQ: FLNA) on TradingView. It offers access to financial statements, statistics, dividend data, and earnings reports, along with segment and regional performance breakdowns. The content is primarily a navigation hub to various financial details …
FLNA
main company
Sharemaestro market context
Stored weekly price path
14 weeks -54.1% · Next-week setup negative 17.6%